Anticipated benefits and surprising effects of daclizumab in multiple sclerosis.
Stüve
Olaf
O
Greenberg
Benjamin M
BM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019002:CD56 Antigen / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000502:physiology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D013601:T-Lymphocytes / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019002:CD56 Antigen; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab